; and (ff) based on achievable and proven criteria measuring pharmacy performance over which the pharmacy has meaningful control and ability to influence. In establishing such standards, the Secretary shall consult with stakeholders, including PDP sponsors and MA organizations, pharmacies across pharmacy practice types, pharmacy benefit managers, patient advocacy organizations, drug manufacturers, appropriate standard-setting organizations, professional pharmacy organizations, and other entities determined appropriate by the Secretary. The Secretary shall review and update the standard pharmacy quality measures on an ongoing basis with appropriate notice and period for comments from stakeholders. (IV) No increase in cost sharing during temporary freeze Subclause (I) shall not apply in the case where application of such subclause would increase the amount owed by an individual in cost sharing above the amount such individual would have owed in cost sharing without application of such subclause. (V) Discrepancies between negotiated prices and actual reimbursement In the case that the Secretary determines that the negotiated price of a PDP sponsor applied at the point-of-sale with respect to a covered part D drug for a year dispensed by a pharmacy was greater than the total reimbursement made to such pharmacy for such drug for such year, such sponsor shall, not later than 90 days after receiving notice of such determination, furnish to the pharmacy that dispensed such drug and to the Secretary a written explanation of why such negotiated price was greater than such reimbursement. (VI) Specialty pharmacy For purposes of carrying out this clause (including subclause (III)(dd)), the Secretary shall, not later than December 31, 2020, define the term specialty pharmacy in consultation with relevant stakeholders. (VII) Definitions In this clause: (aa) Quality measure The term quality measure means criteria used by a PDP sponsor (including an entity that contracts with such sponsor, such as a pharmacy benefit manager) to